Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. - Wikidata - wikimedia - TriplyDB

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

http://www.wikidata.org/entity/Q46567195

about

Long-term efficacy and safety of raltegravir in the management of HIV infection.A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice Raltegravir: The evidence of its therapeutic value in HIV-1 infection.Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.Raltegravir pharmacokinetics during pregnancy.Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.Role of raltegravir in the management of HIV-1 infection.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals Raltegravir: molecular basis of its mechanism of action Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.Clinical pharmacology, efficacy and safety of atazanavir: a review.Drug-drug interactions with raltegravir Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.Role of raltegravir in HIV-1 management.Pharmacology of HIV integrase inhibitors.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.Variability of raltegravir plasma levels in the clinical setting.Effect of raltegravir on the pharmacokinetics of methadone.The effect of raltegravir on the glucuronidation of lamotrigine.Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.No residual activity of raltegravir after development of 148 complex mutations in vivo.A safety evaluation of raltegravir for the treatment of HIV.

P2860

Q27686870-AB2BE849-2289-4E21-A1DE-CA9954F423AA Q27692040-C0CE05D4-C28D-41F0-9ACA-36F053ED629C Q28553066-144AD061-C39A-4F53-BC5D-4B8FB6895136 Q33973930-7CBB80D5-8F8F-4A13-ADE1-E2CA087BAAFD Q34035275-DFFB7210-D1E1-404E-B7CB-E3073EFCDC4B Q34290041-8EEF2CE8-C176-431C-B9B4-929660584DC6 Q34422111-18C0FF90-B9E1-49F1-A144-F75D59AD7030 Q34529127-C16AA6BD-C768-452E-A24B-FEFDB32103AC Q35026582-24C7B961-CED8-4FD4-8536-C1E98A28F6E6 Q35026604-C978CE42-7C6E-4262-A489-18C9B561E6F5 Q35557318-22D67427-356A-45E2-8ADA-C45078CE1522 Q36018556-835953FE-8AD8-40EC-8B1D-039A1CE5255B Q36452171-C8304D56-A677-4CC7-AD8A-388F8720F274 Q36993528-C23009F1-9B9B-48BB-9445-0DF78CDC2C8A Q37378110-5D9E7155-F9C7-4AB9-A0EE-8F67DD180BC5 Q37405336-320DFC48-A192-412B-AC2D-5ADE5A7D0868 Q37551700-89245323-823A-4D52-97A0-6BA92D93224F Q37579219-146394CD-57A4-4C62-B38F-843C9FEE2D27 Q37622972-30777C50-08AC-4076-BE2E-0995AB2B116A Q37644118-6CAFCBA6-F800-4A0D-8B95-96BD7AB992AB Q37779319-73C40A1F-9B51-4598-9785-78BA727D6A6E Q37826300-BD7F61B5-CC52-4777-AA4A-C28B71862F55 Q37857334-7C56B428-043D-4E39-843E-501C234AC9A9 Q38002011-74DC9CC6-6EE7-4516-B947-F5E115DC79E9 Q38025835-AC3DCE54-9C74-4924-9EF4-D857CF35C936 Q38324557-CF3EAEE0-9A0D-467E-9D81-B045DB3D5C71 Q40238083-06A6F1B7-7148-4AB0-BB3C-27E8B2A1FFA9 Q40492253-B092BB15-FAF9-47BD-8D30-18D25D880232 Q41736369-39535597-95EA-475B-BFE9-B9AA32D84486 Q42253719-D1062CE6-1E22-4F7F-8FA5-B07E90E79F05 Q43155085-45A7D6A4-9CD8-4029-9489-FE27570A5F3C Q43283574-85459C1F-4BC7-416D-828B-37739C8984DB Q46095764-C4022AAC-3C91-4F97-9421-2ECC16B29700 Q46151088-6293F7BA-3A30-4E45-93BB-98881FB686E6 Q47377203-0C099D70-573B-41D6-9FA7-4E7BCFC7CF2E

P2860

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

http://www.wikidata.org/entity/Q46567195

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@en

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@nl

type

label

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@en

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@nl

prefLabel

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@en

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@nl

P1433

Q46567195-20F027D6-EEE0-4072-8423-16EBF2B329F1

P1476

Q46567195-8A31A4F8-73B2-4FC7-B261-EEAC6C2E3FEE

P2093

Q46567195-08DAA98F-74E1-4A5D-97B8-F038042DF7FB

Q46567195-1AAE320B-18EA-4386-8972-A10081F28E0A

Q46567195-374988B9-8D2D-4C6D-91E0-8EED403F0148

Q46567195-6DFDA2F6-EA48-4041-B008-010E23CF12F2

Q46567195-7A681192-A162-4D5A-A1A3-E805440AF285

Q46567195-8A390AB2-2AB3-4486-8F53-085531E0C100

Q46567195-B0722210-DC1C-47BF-BE71-D8E78215C8AF

Q46567195-DF502D11-6AC6-476C-A939-B6E48DD53F88

Q46567195-E224BC27-3ABE-4C43-BB4F-E87B410DA4D8

Q46567195-E2CCA963-D9BD-4D11-A5F4-B004EE6929C2

P2860

Q46567195-5258480B-63C0-4A00-8CAE-CBACA81F5B61

Q46567195-6293449B-BF99-4CA5-9E49-8FB9EB6C6D42

Q46567195-812EDD86-D429-4B2A-BA4A-FF5EA7F55733

Q46567195-9AFF09DC-F5B9-48C0-8C10-A35FD88B3BE9

Q46567195-B7CD127A-8050-45FE-BC22-80DCD3CEEF17

Q46567195-E4CEB5D6-6012-4C47-8965-11FA5535C640

P304

Q46567195-F24B99F6-80FD-4BBA-9A64-9250D6D63C8D

P31

Q46567195-E7BC2AC6-A8CF-404D-992F-773439016105

P356

Q46567195-9ECA1266-A4BE-49C0-A711-AA320152949F

P407

Q46567195-C8A6FE98-72A9-48ED-9610-0E59B3E3D2F2

P433

Q46567195-3DB199A1-7C8F-4BAE-BCCF-CF437C2A2166

P478

Q46567195-09B698E0-77DA-46B6-8075-7C68BF3150A7

P50

Q46567195-C020CA6F-C0E8-4FD7-B25A-C69E85EDEC9D

P577

Q46567195-58AF8DC7-BA1E-44E1-8414-8971930A2938

P5875

Q46567195-F00C84D3-4F79-4C95-A942-EF050A657673

P698

Q46567195-3CBA4C6D-13E9-4165-B52D-2F222E6FB418

P356

P1433

Clinical Infectious Diseases

P1476

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

@en

P2093

Amelia S Petry

http://www.w3.org/2001/XMLSchema#string

Goutam C Mistry

http://www.w3.org/2001/XMLSchema#string

John A Wagner

http://www.w3.org/2001/XMLSchema#string

Julie A Stone

http://www.w3.org/2001/XMLSchema#string

Kaylan Ghosh

http://www.w3.org/2001/XMLSchema#string

Keith M Gottesdiener

http://www.w3.org/2001/XMLSchema#string

Larissa A Wenning

http://www.w3.org/2001/XMLSchema#string

Maria J Gutierrez

http://www.w3.org/2001/XMLSchema#string

Marian Iwamoto

http://www.w3.org/2001/XMLSchema#string

Neal Azrolan

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

P304

137-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/588794

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Sheila Breidinger

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5338151

http://www.w3.org/2001/XMLSchema#string

P698

18513146

http://www.w3.org/2001/XMLSchema#string